Guerbet : H1 2024 results at the top end of expectations – revenue growth guidance upgraded (margin unchanged) by 1%
>H1 2024 operating margin: 7.2% (vs 2.4% in H1 2023) - H1 EBITDA came in at € 61m, EBIT at € 30m and net income at € 10m.FCF remains in negative territory (-€ 29m est. vs -€ 72m) and net debt is € 365m, or leverage of 3.2x (vs 3.5x at end-June 2023).In its press release, Guerbet said it expects: i/ revenue growth of over 9% l-f-l vs >8% before (ODDO BHF: +9,5%e), ii/ an adjusted EBITDA margin at a higher level than that seen in 2021 (14.4% / (ODDO BHF: 14.6%...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.